Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Derenofylline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 1.00 |
| ▸ | ACP1 | P24666 | 3/20 | 0.59 |
| ▸ | PDE5A | O76074 | 2/20 | 0.53 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Derenofylline SCHEMBL2832386 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| Derenofylline SCHEMBL24117119 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL14590960 | 0.94 | ADORA1 (0.88) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL14590962 | 0.94 | ADORA1 (0.88) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL14590963 | 0.94 | ADORA1 (0.88) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL14590972 | 0.94 | ADORA1 (0.88) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL8355485 | 0.94 | ADORA1 (0.88) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| Derenofylline SCHEMBL3913966 | 0.93 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| Derenofylline SCHEMBL3913963 | 0.93 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2BACP1 | |
| SCHEMBL4431976 | 0.89 | ADORA1 (0.80) | ADORA1ADORA2AADORA3ADORA2BACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648778-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | National Health Research Institutes (TW) | 2025-11-19 | — | — | EP | claimed |
| WO-2024151651-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2024-07-18 | — | — | WO | claimed |
| US-20100323012-A1 | Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and Diuretics | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-12-23 | — | — | US | claimed |
| EP-1853270-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEP-INHIBITORS, INHIBITORS OF THE ENDOGENOUS ENDOTHELIN PRODUCING SYSTEM AND DIURETICS | Solvay Pharmaceuticals GmbH (DE) | 2007-11-14 | — | — | EP | claimed |
| US-20060205625-A1 | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-09-14 | — | — | US | claimed |
| WO-2006087371-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEP-INHIBITORS, INHIBITORS OF THE ENDOGENOUS ENDOTHELIN PRODUCING SYSTEM AND DIURETICS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-08-24 | — | — | WO | claimed |
| US-20260115217-A1 | TREATMENT OF ONCOGENE-DRIVEN CANCERS | ARCUS BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| EP-3937964-B1 | TREATMENT OF AN ONCOGENENE DRIVEN CANCER HAVING A KRAS OR EGFR MUTATION BY DECREASING ADENOSINE PRODUCTION OR ANTAGONIZING ADENOSINE ACTIVATION | ARCUS BIOSCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250375447-A1 | TREATMENT OF CANCER UTILIZING AN IDENTIFIED ADENOSINE FINGERPRINT | ARCUS BIOSCIENCES INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4660628-A2 | TREATMENT OF ONCOGENE-DRIVEN CANCERS | Arcus Biosciences, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4648778-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | National Health Research Institutes (TW) | 2025-11-19 | — | — | EP | disclosed |
| US-12453738-B2 | Treatment of oncogene-driven cancers | ARCUS BIOSCIENCES, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH | 2006-11-09 | — | — | US | disclosed |
| WO-2006108837-A1 | AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| US-20060205625-A1 | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006087371-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEP-INHIBITORS, INHIBITORS OF THE ENDOGENOUS ENDOTHELIN PRODUCING SYSTEM AND DIURETICS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-08-24 | — | — | WO | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| WO-2003048120-A2 | 2-ARYL PYRROLOGPYRIMIDINES FOR A1 AND A3 RECEPTORS | OSI PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375447-A1 | TREATMENT OF CANCER UTILIZING AN IDENTIFIED ADENOSINE FINGERPRINT | NTPCR, ADORA2A, NT5C2 | ADORA1 19/4885ADORA2A 2/4885ADORA3 12/4885 |
| US-12453738-B2 | Treatment of oncogene-driven cancers | KRAS, HRAS, MYC | ADORA1 915/4885ADORA2A 184/4885ADORA3 974/4885 |
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ABCC9 | ADORA1 363/4885ADORA2A 749/4885ADORA3 115/4885 |
| US-20100323012-A1 | Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and Diuretics | ECE1, EDNRA, MME | ADORA1 50/4885ADORA2A 150/4885ADORA3 124/4885 |
| US-20260115217-A1 | TREATMENT OF ONCOGENE-DRIVEN CANCERS | ADORA2A, KRAS, HRAS | ADORA1 7/4885ADORA2A 1/4885ADORA3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.